Sr. Principal Pharmacometrician Novartis Pharmaceutical Corporation Northborough, Massachusetts, United States
Disclosure(s):
Karthik Lingineni, PhD: No financial relationships to disclose
Currently there are many unknowns in terms of the physiological or PK or dosimetry parameters that drive efficacy of RLTs, and this remains the primary challenge for dose optimization across the prostate cancer programs. The developed integrated model based on VISION sub-study enables us to evaluate the complex dynamic interplay between physiological parameters, tumor dosimetry and efficacy of Lu-PSMA-617.
